

Users of prescription drugs (NHC) – users per 1000 inhabitants, age standardised

Year					2015	2016	2017	2018	2019	2020	2021
Geography	Drug group	Age	Gender								
Troms og Finnmark		0-74 yrs	both genders	641	643	647	648	653	644	659	
			men	570	572	577	578	585	571	588	
			women	720	721	723	725	729	722	736	
		0-44 yrs	both genders	553	554	560	562	572	559	578	
			men	467	469	475	477	487	472	493	
			women	649	650	654	656	665	656	671	
		0-17 yrs	both genders	409	410	426	423	435	413	440	
			men	398	399	414	409	424	398	428	
			women	423	423	439	438	448	429	454	
		18-24 yrs	both genders	641	641	641	641	654	640	645	
			men	454	456	464	470	483	462	473	
			women	854	853	842	836	848	839	836	
Total all drug groups		25-44 yrs	both genders	640	643	642	647	655	651	667	
			men	527	529	529	534	540	535	551	
			women	763	767	765	772	781	779	793	
		45-74 yrs	both genders	796	798	799	799	797	791	801	
			men	751	754	755	755	756	746	755	
			women	844	845	845	847	841	839	850	
		0-79 yrs	both genders	649	651	655	656	661	652	667	
			men	580	582	587	588	594	581	598	
			women	726	727	729	731	735	728	742	
Diabetes drugs (A10)		18-79 yrs	both genders	723	725	725	727	731	725	736	
			men	636	638	640	642	647	638	650	
			women	819	820	818	821	823	820	830	
		0-74 yrs	both genders	28	29	29	30	31	32	37	

	men	32	32	34	34	35	36	40
	women	24	24	25	26	26	27	34
0-44 yrs	both genders	9	9	9	10	10	11	14
	men	9	9	9	10	10	11	12
	women	9	9	10	10	10	12	17
0-17 yrs	both genders	3	3	3	3	4	4	4
	men	3	3	3	3	4	4	4
	women	3	3	3	3	3	3	3
18-24 yrs	both genders	6	6	6	6	7	8	10
	men	6	6	6	6	6	7	7
	women	7	7	7	7	7	9	12
25-44 yrs	both genders	15	15	15	16	17	18	24
	men	15	15	15	16	17	17	20
	women	16	15	16	17	17	20	29
45-74 yrs	both genders	62	63	65	66	67	68	77
	men	72	74	77	78	79	81	89
	women	51	51	52	53	53	54	66
0-79 yrs	both genders	31	31	32	33	33	35	40
	men	34	35	36	37	38	39	43
	women	27	27	27	28	28	30	37
18-79 yrs	both genders	39	40	41	42	43	44	51
	men	44	45	47	48	49	50	55
	women	34	34	35	36	36	38	47
Insulins and analogues (A10A)								
0-74 yrs	both genders	11	11	11	11	12	12	12
	men	12	13	13	13	13	14	14
	women	9	9	9	10	10	10	10
0-44 yrs	both genders	6	5	6	6	6	6	7
	men	6	6	6	6	6	7	7
	women	5	5	5	5	6	6	6
0-17 yrs	both genders	3	3	3	3	3	4	4

	men	3	3	3	3	4	4	4
	women	3	3	3	3	3	3	3
18-24 yrs	both genders	5	5	5	5	5	6	6
	men	5	5	5	5	6	7	6
	women	5	5	5	4	5	6	6
25-44 yrs	both genders	8	8	8	8	8	9	9
	men	8	8	9	9	9	9	9
	women	7	7	7	8	8	8	9
45-74 yrs	both genders	20	21	21	21	21	21	21
	men	24	25	25	25	26	26	26
	women	16	16	16	17	17	16	17
0-79 yrs	both genders	12	12	12	12	12	13	13
	men	13	14	14	14	15	15	15
	women	10	10	10	10	10	10	11
18-79 yrs	both genders	14	15	15	15	15	15	15
	men	17	17	17	17	18	18	18
	women	12	12	12	12	13	13	13
0-74 yrs	both genders	163	162	160	159	157	155	158
	men	166	166	164	164	163	161	164
	women	159	159	155	153	151	149	152
0-44 yrs	both genders	39	39	38	38	38	38	40
	men	36	36	35	36	36	35	36
	women	42	42	41	40	41	40	43
0-17 yrs	both genders	12	12	13	14	16	16	16
	men	12	13	14	16	16	17	18
	women	11	11	13	13	15	14	15
18-24 yrs	both genders	23	23	22	23	24	23	24
	men	16	18	17	16	16	17	16
	women	31	29	29	31	32	29	32
25-44 yrs	both genders	66	66	63	62	62	61	64

Cardiovascular disease, treatment/prevention (C)

	men	61	60	58	59	58	56	58
	women	72	72	68	66	66	66	70
45-74 yrs	both genders	381	379	374	370	365	361	366
	men	396	394	391	390	386	383	388
	women	365	364	356	350	342	339	342
0-79 yrs	both genders	178	178	176	174	173	171	174
	men	182	181	180	180	179	178	180
	women	175	175	171	169	167	165	167
18-79 yrs	both genders	230	229	225	224	221	219	222
	men	234	233	230	230	229	227	230
	women	226	225	220	217	213	211	214
Cardiovascular disease, treatment/prevention, except lipid modifying agents (C except C10)								
0-74 yrs	both genders	141	140	137	136	135	133	135
	men	144	143	141	141	139	138	139
	women	138	137	134	132	130	128	130
0-44 yrs	both genders	36	36	34	34	35	34	36
	men	32	31	30	31	31	31	32
	women	41	40	39	38	39	38	41
0-17 yrs	both genders	12	12	13	14	16	16	16
	men	12	13	14	16	16	17	18
	women	11	11	13	13	15	14	15
18-24 yrs	both genders	22	22	21	22	23	22	23
	men	16	17	16	15	15	16	16
	women	30	28	27	30	31	28	31
25-44 yrs	both genders	60	59	56	55	55	54	56
	men	53	52	49	49	49	47	49
	women	68	68	64	61	61	61	65
45-74 yrs	both genders	325	324	318	315	310	306	308
	men	340	339	335	333	329	325	327
	women	310	308	301	296	290	287	287
0-79 yrs	both genders	155	155	152	151	150	148	149

		men	158	158	155	155	154	153	154
		women	153	152	148	147	145	143	145
Lipid modifying agents (C10)	18-79 yrs	both genders	199	199	194	193	191	189	190
		men	203	202	199	198	196	194	196
		women	196	195	190	188	185	183	184
	0-74 yrs	both genders	76	75	75	74	72	71	73
		men	87	86	87	87	86	85	87
		women	65	64	62	61	58	57	59
	0-44 yrs	both genders	6	6	6	6	6	6	6
		men	8	8	8	8	8	7	8
		women	4	4	4	4	4	4	4
	0-17 yrs	both genders	0	0	0	0	0	0	0
		men	:	:	:	:	:	:	:
		women	:	:	:	:	:	:	:
	18-24 yrs	both genders	1	1	1	1	1	1	1
		men	1	1	:	:	1	1	:
		women	1	1	:	:	1	1	:
	25-44 yrs	both genders	12	13	13	13	12	11	13
		men	17	17	18	18	17	15	17
		women	7	8	8	8	8	7	9
	45-74 yrs	both genders	199	196	195	194	189	186	191
		men	225	222	224	224	222	221	226
		women	172	169	164	161	154	151	155
	0-79 yrs	both genders	86	85	85	84	83	82	84
		men	97	97	:	:	97	96	:
		women	74	73	:	:	68	67	:
	18-79 yrs	both genders	112	111	111	110	108	107	109
		men	127	127	127	128	126	126	129
		women	97	95	94	92	89	87	89
Painkillers (analgetics) (M01A, N02A, N02B)	0-74 yrs	both genders	210	210	213	212	212	212	220

		men	181	180	183	181	181	180	186			
		women	242	243	245	245	246	247	257			
0-44 yrs		both genders	141	141	143	141	143	140	147			
		men	119	118	121	119	120	117	121			
		women	166	166	167	166	168	166	176			
0-17 yrs		both genders	25	25	28	27	28	25	30			
		men	20	18	24	21	24	19	24			
		women	31	32	32	33	34	32	37			
18-24 yrs		both genders	152	150	149	150	151	142	151			
		men	117	116	113	116	116	104	111			
		women	192	189	190	189	192	184	196			
25-44 yrs		both genders	232	232	234	232	234	233	242			
		men	201	199	203	200	200	200	204			
		women	267	268	268	266	270	270	283			
45-74 yrs		both genders	331	332	336	336	334	339	348			
		men	289	289	292	290	288	292	300			
		women	376	379	382	384	382	388	399			
0-79 yrs		both genders	215	214	217	216	216	216	224			
		men	184	183	187	185	184	183	190			
		women	247	248	249	250	250	251	261			
18-79 yrs		both genders	273	272	275	274	274	275	284			
		men	235	233	237	235	233	234	241			
		women	313	314	316	316	317	318	330			
Antiinflammatory and antirheumatic products, non-steroids (M01A)		0-74 yrs	both genders	148	145	146	142	140	139	145		
			men	127	123	125	121	119	117	121		
			women	170	169	169	164	163	163	171		
0-44 yrs			both genders	105	103	104	100	102	99	105		
			men	89	85	88	85	85	81	87		
			women	122	122	121	117	120	119	126		
0-17 yrs			both genders	20	18	21	20	21	19	23		

	men	15	12	17	15	16	13	17
	women	25	24	26	25	27	25	29
18-24 yrs	both genders	114	109	107	105	107	100	110
	men	88	83	79	82	80	70	78
	women	143	138	139	131	138	133	145
25-44 yrs	both genders	171	169	170	165	165	165	171
	men	150	145	149	143	142	140	146
	women	193	195	192	189	191	191	198
45-74 yrs	both genders	224	220	220	214	207	210	214
	men	193	189	189	183	178	180	182
	women	256	253	253	246	237	241	249
0-79 yrs	both genders	148	145	146	142	140	139	145
	men	127	123	125	120	118	117	121
	women	171	169	169	164	163	163	170
18-79 yrs	both genders	188	185	184	179	176	176	182
	men	162	157	158	153	150	149	153
	women	216	214	212	207	205	205	213
0-74 yrs	both genders	97	97	97	95	93	92	94
	men	86	86	86	84	83	82	84
	women	109	109	109	107	105	102	104
0-44 yrs	both genders	63	64	64	63	62	61	61
	men	53	54	55	54	53	53	52
	women	75	74	74	73	71	69	70
0-17 yrs	both genders	6	6	6	6	6	6	7
	men	5	5	6	5	5	5	6
	women	8	8	7	8	7	7	7
18-24 yrs	both genders	67	66	68	68	68	64	65
	men	50	50	51	51	52	48	50
	women	87	84	88	88	86	81	81
25-44 yrs	both genders	109	110	110	108	105	104	104

Painkillers, Opioids (N02A)

		men	94	96	97	96	93	94	91
		women	125	125	124	121	118	116	118
45-74 yrs	both genders	156	156	155	151	148	147	151	
	men	143	141	141	137	134	134	139	
	women	170	171	171	167	163	161	163	
0-79 yrs	both genders	100	99	99	97	95	94	95	
	men	88	87	88	86	84	84	85	
	women	112	112	112	109	107	104	106	
18-79 yrs	both genders	128	128	128	125	122	121	123	
	men	113	113	113	111	109	108	110	
	women	144	144	144	141	137	134	137	
Painkillers, other (N02B)	0-74 yrs	both genders	74	78	85	91	99	106	112
	men	56	59	65	70	74	80	85	
	women	94	98	106	114	126	133	141	
0-44 yrs	both genders	43	44	49	52	58	60	65	
	men	32	33	38	40	43	44	49	
	women	55	56	62	64	75	77	84	
0-17 yrs	both genders	7	7	8	8	10	9	10	
	men	5	6	7	7	9	8	8	
	women	8	8	9	9	11	10	13	
18-24 yrs	both genders	37	36	43	46	56	51	56	
	men	27	27	31	34	38	34	39	
	women	49	47	56	61	76	70	75	
25-44 yrs	both genders	74	77	85	89	99	105	114	
	men	55	58	65	69	73	78	85	
	women	95	99	107	111	127	134	144	
45-74 yrs	both genders	129	136	148	161	171	185	194	
	men	99	104	113	122	130	143	150	
	women	161	170	184	201	215	230	240	
0-79 yrs	both genders	77	81	88	95	103	109	116	

		men	59	61	68	72	77	83	89
		women	97	101	110	118	130	137	145
Antimigraine preparations (N02C)	18-79 yrs	both genders	99	103	113	121	131	140	148
		men	75	78	86	92	98	106	114
		women	125	130	141	151	167	176	185
Drugs for mental disorders, incl. hypnotics (N05A, N05C, N05B, N06A)	0-74 yrs	both genders	21	22	23	24	25	25	27
		men	8	8	8	9	10	9	10
		women	36	36	38	40	42	43	45
	0-44 yrs	both genders	19	19	20	21	22	23	24
		men	8	8	8	9	9	9	9
		women	31	32	34	35	36	38	41
	0-17 yrs	both genders	6	5	6	7	7	7	8
		men	4	4	4	5	5	5	5
		women	8	7	8	9	9	10	11
	18-24 yrs	both genders	20	21	24	25	27	25	26
		men	7	9	8	10	10	8	11
		women	36	35	43	42	46	44	44
	25-44 yrs	both genders	29	30	30	32	33	35	37
		men	11	11	10	11	12	12	12
		women	49	51	52	55	55	60	63
	45-74 yrs	both genders	25	26	27	29	30	30	31
		men	8	9	9	10	10	10	10
		women	44	44	46	49	51	50	53
	0-79 yrs	both genders	21	21	22	24	25	25	26
		men	8	8	8	9	9	9	9
		women	35	36	38	40	41	42	44
	18-79 yrs	both genders	26	26	27	29	30	30	32
		men	9	10	9	10	11	11	11
		women	43	44	47	49	51	52	54

		men	41	41	41	41	42	42	44		
		women	69	70	70	71	72	74	78		
0-44 yrs	both genders		37	38	38	39	40	41	45		
	men		29	29	30	29	30	31	33		
	women		47	48	48	50	50	53	58		
0-17 yrs	both genders		3	3	3	3	3	3	4		
	men		2	2	2	2	2	2	2		
	women		4	4	3	4	4	5	6		
18-24 yrs	both genders		44	43	47	45	44	46	52		
	men		31	29	29	29	30	30	32		
	women		59	59	67	64	59	64	73		
25-44 yrs	both genders		63	65	65	67	68	71	75		
	men		50	52	52	52	53	55	57		
	women		78	79	78	82	84	88	95		
45-74 yrs	both genders		84	84	84	85	86	86	88		
	men		61	61	61	62	62	62	63		
	women		108	109	108	109	110	111	114		
0-79 yrs	both genders		56	56	56	57	57	59	61		
	men		41	42	42	42	42	43	44		
	women		71	71	71	73	73	75	79		
18-79 yrs	both genders		72	72	72	73	74	75	79		
	men		53	54	54	54	55	55	57		
	women		91	92	92	94	94	97	102		
Antipsychotics (N05A)		0-74 yrs	both genders	16	17	17	18	17	18	18	
			men	15	15	16	16	16	16	17	
			women	18	18	18	19	19	19	20	
		0-44 yrs	both genders	11	11	12	13	12	13	14	
			men	11	11	11	12	12	12	13	
			women	11	11	12	14	12	13	15	
		0-17 yrs	both genders	1	1	1	1	1	1	1	

	men	1	1	1	1	1	1	1
	women	1	1	1	1	1	1	2
18-24 yrs	both genders	13	13	14	14	13	14	15
	men	11	10	11	11	12	12	12
	women	14	15	17	17	15	16	19
25-44 yrs	both genders	19	19	20	22	21	22	23
	men	19	19	20	20	21	21	22
	women	19	18	20	23	21	22	24
45-74 yrs	both genders	26	26	26	26	26	27	26
	men	23	23	23	23	23	24	23
	women	30	29	29	30	30	30	30
0-79 yrs	both genders	17	17	17	18	17	18	18
	men	15	16	16	16	16	16	17
	women	18	18	18	20	19	19	20
18-79 yrs	both genders	22	22	22	23	23	23	24
	men	20	20	21	21	20	21	21
	women	24	23	24	26	25	25	26
0-74 yrs	both genders	44	44	44	44	45	46	49
	men	30	30	30	31	31	31	33
	women	58	59	59	59	60	63	66
0-44 yrs	both genders	30	31	31	31	32	34	36
	men	22	22	22	22	22	23	24
	women	40	41	41	42	43	45	50
0-17 yrs	both genders	2	2	2	2	2	3	4
	men	1	2	2	1	1	1	1
	women	3	4	3	3	3	4	6
18-24 yrs	both genders	36	35	38	37	36	38	42
	men	23	22	21	21	22	22	25
	women	50	51	58	54	51	55	62
25-44 yrs	both genders	52	53	52	53	55	57	61

Antidepressants (N06A)

		men	38	39	39	39	40	41	43		
		women	67	68	67	69	72	76	81		
45-74 yrs	both genders	66	67	67	67	69	69	71			
	men	45	45	45	46	47	46	48			
	women	89	91	90	90	91	93	96			
0-79 yrs	both genders	45	45	45	45	46	47	50			
	men	31	31	31	31	32	32	33			
	women	59	60	60	61	61	63	67			
18-79 yrs	both genders	57	58	58	59	60	61	64			
	men	40	40	40	40	41	41	43			
	women	76	78	78	78	79	82	86			
Hypnotics, sedatives and anxiolytics (N05C, N05B)		0-74 yrs	both genders	83	82	82	81	83	83	85	
			men	62	62	63	63	64	64	65	
			women	104	103	103	101	104	103	105	
		0-44 yrs	both genders	46	46	48	49	52	53	55	
			men	38	39	41	41	44	44	46	
			women	55	54	56	57	61	62	65	
		0-17 yrs	both genders	12	12	13	14	17	18	23	
			men	12	12	15	14	18	20	22	
			women	11	11	12	14	16	17	23	
		18-24 yrs	both genders	43	45	49	49	54	54	55	
			men	33	35	36	37	41	39	40	
			women	55	56	64	63	69	70	71	
		25-44 yrs	both genders	75	75	76	77	80	80	82	
			men	62	63	64	65	66	66	68	
			women	90	88	88	91	95	96	98	
		45-74 yrs	both genders	146	145	142	138	138	135	136	
			men	104	103	100	100	99	97	99	
			women	191	188	185	178	179	175	175	
		0-79 yrs	both genders	87	86	86	85	87	86	88	

		men	65	65	65	65	66	66	68
		women	110	108	108	107	108	107	110
Hypnotics, addictive (N05C excl. N05CH01 and N05CD08)	18-79 yrs	both genders	110	109	108	107	108	107	108
		men	82	82	81	81	81	80	81
		women	140	138	137	135	137	135	136
		both genders	48	47	46	45	44	42	41
ADHD drugs (Attention Deficit Hyperactivity Disorder) (C02AC02 and N06BA except N06BA07)	0-74 yrs	men	35	35	33	33	32	31	30
		women	62	60	58	57	56	54	53
		both genders	21	21	20	20	20	19	19
	0-44 yrs	men	18	17	17	16	16	15	15
		women	25	24	23	24	24	23	23
		both genders	1	1	1	1	1	1	1
	0-17 yrs	men	1	1	1	1	1	1	1
		women	1	1	1	1	1	1	1
		both genders	16	16	16	14	15	15	14
	18-24 yrs	men	12	13	11	10	11	11	10
		women	21	19	21	19	19	19	19
		both genders	40	38	37	37	37	36	35
	25-44 yrs	men	33	32	31	31	30	29	28
		women	47	45	43	44	44	43	42
		both genders	96	94	91	88	86	83	80
	45-74 yrs	men	66	65	63	62	60	58	56
		women	126	124	120	115	114	108	105
		both genders	52	51	49	48	47	45	44
	0-79 yrs	men	38	37	35	35	34	33	32
		women	67	65	63	61	60	58	57
		both genders	68	66	63	62	61	59	57
	18-79 yrs	men	49	48	46	46	44	43	41
		women	87	85	82	80	78	76	74
		both genders	7	8	8	8	9	10	13

	men	9	9	9	10	11	12	15			
	women	6	5	6	6	7	9	10			
0-44 yrs	both genders	10	11	11	11	13	14	17			
	men	13	13	13	14	15	17	20			
	women	8	8	9	9	10	12	14			
0-17 yrs	both genders	14	14	13	13	13	15	18			
	men	20	20	19	18	20	21	25			
	women	7	7	7	6	7	8	11			
18-24 yrs	both genders	12	11	13	13	14	15	18			
	men	13	13	14	14	15	16	19			
	women	11	9	12	12	12	14	18			
25-44 yrs	both genders	7	8	9	10	12	14	16			
	men	7	8	8	10	11	14	17			
	women	7	8	9	10	12	14	16			
45-74 yrs	both genders	2	2	2	3	3	4	4			
	men	2	2	3	3	3	4	4			
	women	2	2	2	2	3	3	4			
0-79 yrs	both genders	:	:	:	:	:	:	:			
	men	:	:	:	:	:	:	:			
	women	:	:	:	:	:	:	:			
18-79 yrs	both genders	:	:	:	:	:	:	:			
	men	:	:	:	:	:	:	:			
	women	:	:	:	:	:	:	:			
Asthma and chronic obstructive pulmonary disease (COPD) drugs (R03 except R03CA)		0-74 yrs	both genders	83	85	87	87	89	88	91	
			men	75	76	78	79	80	79	82	
			women	92	94	96	97	98	98	100	
		0-44 yrs	both genders	67	68	69	69	70	69	74	
			men	65	65	66	66	67	65	71	
			women	69	72	72	71	73	73	78	
		0-17 yrs	both genders	78	78	78	77	78	72	85	

	men	89	86	86	86	87	81	93
	women	68	69	70	68	69	63	76
18-24 yrs	both genders	54	59	61	57	60	63	60
	men	44	47	50	47	48	50	48
	women	65	72	73	69	73	77	73
25-44 yrs	both genders	62	64	64	66	67	69	70
	men	53	54	55	57	58	58	60
	women	72	74	73	75	77	81	81
45-74 yrs	both genders	112	114	118	120	121	121	121
	men	93	96	100	101	101	102	102
	women	131	133	137	141	142	142	140
0-79 yrs	both genders	86	87	89	90	91	91	94
	men	78	79	81	81	82	81	84
	women	94	96	98	99	101	101	103
18-79 yrs	both genders	88	90	93	94	95	97	96
	men	74	77	79	80	81	81	82
	women	102	105	107	109	111	113	112
0-74 yrs	both genders	134	137	144	147	152	153	161
	men	107	110	113	117	121	122	130
	women	164	168	177	180	185	187	194
0-44 yrs	both genders	123	126	132	136	141	142	152
	men	105	108	111	115	120	121	131
	women	143	146	155	159	165	165	175
0-17 yrs	both genders	90	91	96	97	100	101	109
	men	95	98	102	103	105	108	117
	women	85	85	90	91	95	93	101
18-24 yrs	both genders	133	141	152	155	161	159	166
	men	106	108	117	118	121	121	125
	women	165	179	193	198	206	201	211
25-44 yrs	both genders	146	149	155	161	168	171	182

Antihistamines (allergy medicines) (R06A, R01AC, R01AD, R01B, S01G)

		men	112	115	118	124	131	133	144		
		women	182	185	195	200	208	212	223		
45-74 yrs	both genders		155	158	164	168	171	173	178		
	men		110	113	117	121	123	123	129		
	women		202	205	214	218	220	225	229		
0-79 yrs	both genders		134	137	144	147	152	153	161		
	men		106	109	113	117	121	122	130		
	women		164	167	176	180	185	187	194		
18-79 yrs	both genders		148	151	158	163	168	169	177		
	men		110	113	117	121	126	126	134		
	women		188	193	202	207	212	215	223		
Antihistamines for systemic use (R06)		0-74 yrs	both genders	96	99	103	107	111	117	120	
			men	74	77	80	83	86	90	94	
			women	120	123	129	133	138	145	148	
		0-44 yrs	both genders	90	93	99	102	107	113	117	
			men	78	80	85	88	91	96	101	
			women	105	108	114	118	124	131	134	
		0-17 yrs	both genders	75	75	80	82	84	87	93	
			men	79	80	85	88	88	92	99	
			women	70	70	75	77	80	81	86	
		18-24 yrs	both genders	100	106	113	117	122	128	130	
			men	81	82	87	90	93	98	101	
			women	122	134	143	148	155	162	163	
		25-44 yrs	both genders	100	104	109	113	120	128	132	
			men	75	80	83	88	93	98	103	
			women	127	130	137	141	150	161	164	
		45-74 yrs	both genders	106	108	112	116	118	124	125	
			men	67	70	71	75	77	80	82	
			women	147	149	155	159	162	169	171	
		0-79 yrs	both genders	96	98	103	107	111	116	120	

		men	73	76	79	83	86	89	94
		women	120	122	129	132	138	145	147
18-79 yrs	both genders	102	106	110	114	119	125	128	
		72	75	77	81	85	89	92	
	men	135	138	145	150	155	164	166	
	women								

CellMark Legend

- .. Missing data
- . Not possible to calculate
- : Hidden value

Description

Users of prescription drugs among 0-79 year olds. Users are defined as people who have been dispensed at least one prescription in the reporting period.

Four measures are available. Use the Measures menu to select:

1. number of users (shown on national level only due to privacy protection)
2. users per 1000 = number of users per 1000 inhabitants of same sex and age per year
3. users per 1000 age standardized = number of users per 1000 inhabitants of same sex and age per year, age standardised. Age standardisation of rates reduces the effect of differing age distributions when groups are compared over time and between geographical regions.
4. Ratio (Norway=100): The ratio between the standardized rate in the county and the national rate for a given year. A ratio of 130 means that the county rate is 30 % higher than the national rate. A ratio of 87 means that the county rate is 13 % lower than the national level.

In the Norwegian Prescription Database, every individual is registered with a pseudonymous serial number which makes it possible to link drug consumption to individuals without knowing who they are. Even if a person has dispensed a prescription for the same drug several times, they are only counted as a user once.

Drug consumption cannot be assumed to be synonymous with disease prevalence. The exception is the use of drugs to treat diabetes mellitus, which can be considered a good indicator for prevalence of diabetes. A lot of patients use multiple drugs, e.g. both anti-depressives and hypnotics, so will be included in both groups. It is therefore not possible to simply add the number of users in two groups of drugs to find out how many users there are in total.

Figures in Norhealth may vary slightly from the Norwegian Prescription Database because data may have been extracted from the main database at different times.

Drugs are classified according to the ATC system (see below).

The following groups of drugs are included *:

All drugs in total

Diabetes drugs (A10)

- Insulins and analogues (A10A)

Cardiovascular disease, treatment/prevention (C)

- Cardiovascular disease, treatment/prevention, except Lipid modifying agents (C except C10)

- Lipid modifying agents (C10)

Painkillers (analgetics) (M01A, N02A, N02B)

- Antiinflammatory and antirheumatic products, non-steroids (M01A)

- Painkillers, Opioids (N02A)

- Painkillers, other (N02B)

- Antimigraine preparations (N02C)

Drugs for mental disorders (N05A, N06A)

- Antipsychotics (N05A)

- Antidepressants (N06A)

Hypnotics and anxiolytics (N05B, N05C)

- Hypnotics (N05C)

- Hypnotics, addictive (N05C excl. N05CH01 and N05CD08)

ADHD drugs (Attention Deficit Hyperactivity Disorder) (C02AC02 and N06BA except N06BA07)

Asthma and chronic obstructive pulmonary disease (COPD) drugs (R03 except R03CA)

Antihistamines (allergy medicines) (R06A, R01AC, R01AD, R01B, S01G)

- Antihistamines for systemic use (R06A)

Prescriptions for antibiotics are presented in a separate, neighbouring table.

Data on Blood glucose lowering drugs, excluding insulins (A10B) are presented under Health and disease/ Disease groups/ Type 2 diabetes, indicators.

News, March 2019:

- New subgroup: Hypnotics, addictive - comprising all hypnotics except melatonin and midazolam.

- ADHD drugs now include guanfacin (C02AC02).

- Drugs against asthma and chronic obstructive pulmonary disease (COPD) now exclude R03CA. The former group "Asthma and COPD (R03)" has been discontinued.

Drugs are classified according to the ATC-system (Anatomic, Therapeutic, Chemical classification). By using this international classification system one can make statistics of drug consumption groups at 5 different levels, including from figures that show total use of all preparations classified under a main group (1st level, e.g. group C - Heart and circulation), figures for the different sub-groups (2nd, 3rd and 4th level) and down to figures that show use of each active ingredient.

Further information about the Norwegian Prescription Database can be found at www.norpdp.no.

See also Drug Consumption in Norway at www.drugconsumption.no.

* Some of the drugs can be bought without a prescription, e.g. in small packages. Such use is not included in the statistics.

Rationale for indicator

For many diseases, we have insufficient data on prevalence. Drug use is not synonymous with disease prevalence, but can be an indicator for the prevalence of a disease.

Source

Norwegian Institute of Public Health, Department of Pharmacoepidemiology

Collection

The Norwegian Prescription Database contains information on all prescriptions dispensed from Norwegian pharmacies for both human and animal use. The register only contains information that directly or indirectly concerns prescriptions. Information about the patient and prescriber is pseudonymous.

Interpretation and sources of error

Purchases of over the counter drugs from a pharmacy or grocery store are not included. People over 80 years are excluded because there are varying proportions in each county who live at institutions where drugs are provided by the institution rather than via private prescriptions. Figures are also not presented for inappropriate combinations of age and drug groups, for example anti-dementia medicines for children.

Data quality

The data quality is very good.

Statistical analysis

Age standardization is done using direct standardization. The standard population is the sum of men and women in each age group in Norway per 1.January 2012.

When numbers are missing

Statistics based on fewer than five cases are hidden for privacy reasons. The same is done where the population segment from which the data are collected is less than ten.

If more than 20 per cent of the numbers in a time series are hidden for privacy reasons, the entire time series is concealed so as not to create a false impression of the situation in the county. Time series are also hidden where more than 50 per cent of the numbers in the time series are based on 6 or fewer cases.

Time periods

Geographical level

Country, health region, counties

Gender

Both genders, men, women

Age groups

0-74 years, 0-44 years (0-17, 18-24, 25-44), 45-74 years. Additionally, 0-79 years and 18-79 years.

Frequency of updates

Annually

Last updated

4/27/22

Keywords

Click on a keyword to search for similar indicators.

- Antibiotics
- Antihypertensives
- Antipsychotics
- Anxiety
- Asthma
- Betablockers
- Blood lipids
- Blood pressure
- Blood sugar
- Calcium antagonists
- Cholesterol
- Contraceptives
- Dementia
- Diabetes
- Drugs
- Estrogen
- Hypertension
- Hypnotics
- Insulin
- Medicine
- Menopause
- Obesity
- Prescription database
- Sedatives

Fact sheets

Below are links to relevant fact sheets, articles and reports. These may describe trends over time in the Norwegian population or differences by sex, age group, geographical region or socioeconomic status:

- [Topic: Drug consumption](#)
- [Topic: Pain](#)
- [Facts on hypertension \(in Norwegian only\)](#)
- [Chronic Obstructive Pulmonary Disease \(COPD\) in Norway - Public Health Report](#)